Author

Brian J. Abraham

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Sep 2026

Abstract B005: Synergistic targeting of EP300/CBP and EYA co-activators collapses the rhabdomyosarcoma core regulatory circuit

Rhabdomyosarcoma (RMS) is a high-risk pediatric sarcoma that resembles developing skeletal muscle. Transcriptional dysregulation drives RMS pathogenesis in tumors carrying chimeric transcription factors (“fusion-positive (FP)”), and those without (“fusion-negative” (FN)). Here, we develop a novel approach against RMS...

Brian J. Abraham, Annika L. Gustafson, S. Nance et al. · Cancer Research · 0 citations

Sep 2026

Abstract IA06: Myogenic and neural transcriptional circuitry determines PAX3::FOXO1-driven initiation of rhabdomyosarcoma

Rhabdomyosarcoma (RMS) is the most common pediatric soft tissue sarcoma. Alveolar RMS (ARMS) has a poor prognosis and is driven by either t(2;13)(q35;q14) or t(1;13)(p36;q14) translocations resulting in the PAX3::FOXO1 (P3F) and PAX7::FOXO1 (P7F) fusion oncoproteins, respectively. Current in vivo model systems fail t...

Bradley T. Stevens, Yang E. Zhang, Matthew R. Garcia et al. · Cancer Research · 0 citations

Sep 2026

Abstract B011: Oncogenic neomorphic ATRX-in-frame fusion mutations mechanistically enforce a new immunotherapeutic vulnerability through altered epigenomic regulation

Children with high-risk neuroblastomas (NB) marked by in-frame fusion mutations in the ATRX chromatin remodeler (“ATRX-IFF”) display highly chemoresistant disease. As a result, despite multi-modality therapies, these children have poor overall survival. At present, there are no molecularly-targeted agents for these t...

M. A. Mohammad Nezhady, S. Sati, D. E. Prado et al. · Cancer Research · 0 citations